The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to test for actionable somatic mutations in solid tumors.
|Highly accurate||>99% sensitivity and specificity*|
|Comprehensive||>99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials†|
|Actionable||Delivers insights to guide targeted therapy or clinical trial selection|
|Advanced||Powered by the Oncomine platform, a next-generation sequencing solution used by leading global research institutions and clinical trials, including the NCI-MATCH trial|
*Compared against a series of cases with known or previously-tested mutations by other NGS methods.
† Based on an analysis of actionable alterations from OncoKB. For additional information, please see Chakrevarty D, Gao K, Phillips S, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology. 2017.